scispace - formally typeset
O

Onkabetse Julia Molefe-Baikai

Researcher at University of Botswana

Publications -  10
Citations -  147

Onkabetse Julia Molefe-Baikai is an academic researcher from University of Botswana. The author has contributed to research in topics: Atrial fibrillation & Population. The author has an hindex of 5, co-authored 8 publications receiving 56 citations.

Papers
More filters
Journal ArticleDOI

The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation.

TL;DR: INVICTUS is the largest program of clinical research focused on a neglected cardiovascular disease and will provide new information on the clinical course of patients with RHD, and approaches to anticoagulation in those with concomitant AF.
Journal ArticleDOI

Benefits and Risks of Statin Therapy in the HIV-Infected Population

TL;DR: Pitavastatin is the statin of choice for the ongoing largest trial (6500 participants) to test the benefits of statin therapy among HIV-infected adults and is underutilized in the prevention of CVD in HIV- Infected populations based on criteria in established cholesterol guidelines.
Journal ArticleDOI

Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study.

TL;DR: Patients with T2DM in Gaborone, Botswana, presented with suboptimal control of recommended glycaemic, hypertension and LDL-C targets, calling for urgent individual and health systems interventions to address key determinants of the recommended therapeutic targets among patients with diabetes.
Journal ArticleDOI

The prevalence of microalbuminuria and associated factors among patients with type 2 diabetes mellitus in Botswana

TL;DR: High prevalence of Microalbuminuria raises an urgent need for changes in the management of patients with type 2 DM in Botswana, with emphasis on prevention and reduction of MA to avoid development of overt diabetic nephropathy and ensuing cardiovascular morbidity and mortality.